Company Filing History:
Years Active: 2002-2022
Title: Xinjie Lu: Innovator in Atherosclerosis Research
Introduction
Xinjie Lu is a prominent inventor based in London, GB. He has made significant contributions to the field of immunology, particularly in the development of vaccines targeting atherosclerosis. With a total of 3 patents to his name, his work is paving the way for innovative treatments in this critical area of health.
Latest Patents
Xinjie Lu's latest patents include a Multi-epitopic construct and an Anti-atheroma vaccine. The Multi-epitopic construct relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. These antigenic determinants are associated with different pathways leading to atherosclerosis. The invention aims to elicit an immune response against antigens and pathogens involved in the development of atherosclerosis, including methods of treating and/or preventing the disease and recombinant protein products. The Anti-atheroma vaccine comprises a recombinant protein that includes a carrier portion, a first epitope capable of eliciting an anti-atheroma response, and a second epitope capable of eliciting an anti-atheroma response, characterized by the distinct nature of the first and second epitopes.
Career Highlights
Throughout his career, Xinjie Lu has worked with notable organizations such as the Thrombosis Research Institute and Trigen GmbH. His experience in these institutions has allowed him to collaborate on groundbreaking research and development projects.
Collaborations
Xinjie Lu has collaborated with esteemed colleagues, including Vijay Vir Kakkar and Michael Finbarr Scully. These partnerships have further enhanced his research capabilities and contributed to the advancement of his innovative work.
Conclusion
Xinjie Lu's contributions to the field of atherosclerosis research through his patents and collaborations highlight his role as a leading inventor. His work continues to inspire advancements in immunology and vaccine development.